INDICATIONS AND USAGE
ADVAIR DISKUS is indicated for the long-term, twice-daily, maintenance treatment of asthma in patients 12 years of age and older. ADVAIR DISKUS is NOT indicated for the relief of acute bronchospasm. Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis: ADVAIR DISKUS 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with COPD associated with chronic bronchitis.
ADVAIR DISKUS 250/50 mcg twice daily is the only approved dosage for the treatment of COPD associated with chronic bronchitis. Higher doses, including ADVAIR DISKUS 500/50, are not recommended (see DOSAGE AND ADMINISTRATION: Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis).
The benefit of treating patients with COPD associated with chronic bronchitis with ADVAIR DISKUS 250/50 for periods longer than 6 months has not been evaluated. Patients who are treated with ADVAIR DISKUS 250/50 for COPD associated with chronic bronchitis for periods longer than 6 months should be reevaluated periodically to assess the continuing benefits and potential risks of treatment. ADVAIR DISKUS is NOT indicated for the relief of acute bronchospasm.
DOSAGE AND ADMINISTRATION
ADVAIR DISKUS should be administered by the orally inhaled route only (see Patient?s Instructions For Use). After inhalation, the patient should rinse the mouth with water without swallowing. ADVAIR DISKUS should not be used for transferring patients from systemic corticosteroid therapy. Asthma: ADVAIR DISKUS is available in 3 strengths, ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50, containing 100, 250, and 500 mcg of fluticasone propionate, respectively, and 50 mcg of salmeterol per inhalation.